- Home
- SOPH vs GOSS Comparison
SOPH vs GOSS Comparison
Compare SOPH & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- GOSS
- Stock Information
- Founded
- SOPH 2011
- GOSS 2015
- Country
- SOPH Switzerland
- GOSS United States
- Employees
- SOPH N/A
- GOSS N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- SOPH Health Care
- GOSS Health Care
- Exchange
- SOPH Nasdaq
- GOSS Nasdaq
- Market Cap
- SOPH 247.0M
- GOSS 214.7M
- IPO Year
- SOPH 2021
- GOSS 2019
- Fundamental
- Price
- SOPH $3.39
- GOSS $0.94
- Analyst Decision
- SOPH Strong Buy
- GOSS Strong Buy
- Analyst Count
- SOPH 3
- GOSS 5
- Target Price
- SOPH $7.00
- GOSS $9.20
- AVG Volume (30 Days)
- SOPH 28.4K
- GOSS 943.4K
- Earning Date
- SOPH 11-05-2024
- GOSS 11-07-2024
- Dividend Yield
- SOPH N/A
- GOSS N/A
- EPS Growth
- SOPH N/A
- GOSS N/A
- EPS
- SOPH N/A
- GOSS N/A
- Revenue
- SOPH $64,938,000.00
- GOSS $95,842,000.00
- Revenue This Year
- SOPH $7.70
- GOSS N/A
- Revenue Next Year
- SOPH $20.61
- GOSS N/A
- P/E Ratio
- SOPH N/A
- GOSS N/A
- Revenue Growth
- SOPH 20.14
- GOSS N/A
- 52 Week Low
- SOPH $2.70
- GOSS $0.45
- 52 Week High
- SOPH $7.37
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- SOPH 42.48
- GOSS 45.42
- Support Level
- SOPH $3.03
- GOSS $0.93
- Resistance Level
- SOPH $3.54
- GOSS $1.09
- Average True Range (ATR)
- SOPH 0.23
- GOSS 0.06
- MACD
- SOPH -0.02
- GOSS -0.01
- Stochastic Oscillator
- SOPH 33.18
- GOSS 7.37
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.